High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.
Lancet OncolSep 1, 2026
Christophe Hennequin, Paul Sargos, Lise Roca et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, open-label, randomized phase 3 trial evaluated the impact of dose-escalated radiotherapy (80 Gy) versus standard radiotherapy (70 Gy) on progression-free survival in 505 men with high-risk prostate cancer receiving long-term androgen deprivation therapy. The study found that 5-year progression-free survival was 91.4% in the dose-escalation group compared to 88.1% in the control group.
Key findings
- 5-year progression-free survival was 91.4% in the dose-escalation group versus 88.1% in the control group.
- 10-year progression-free survival was 83.6% for the dose-escalation group compared to 72.2% for the control group.
- Grade 3 or worse adverse events occurred in 24% of the dose-escalation group and 25% of the control group.
Why it matters
The findings suggest that higher doses of radiotherapy may enhance progression-free survival in high-risk prostate cancer patients, which could influence treatment strategies and patient outcomes in this population.